| Literature DB >> 28771617 |
Tormund S Njølstad1,2,3, Henrica M Werner1,2,3, Janusz Marcickiewicz4,5, Solveig Tingulstad6, Anne C Staff7, Klaus Oddenes8, Line Bjørge1,2,3, Marie E Engh9, Kathrine Woie1,2,3, Jostein Tjugum10, Margaret S Lode11, Frederic Amant12,13, Helga B Salvesen1,2,3, Jone Trovik1,2,3.
Abstract
Surgery is the cornerstone in primary endometrial cancer treatment, and with curative intent it constitutes total hysterectomy and bilateral salpingo-oopherectomy. In addition, lymphadenectomy is performed in selected patients dependent on a preoperative risk assessment. Recent reports from the surgical approach to esophageal cancer reveal worse outcome when esophagectomy is performed later in the week. On this basis, we set out to explore weekday of surgery in relation to long-term outcome in 1302 endometrial cancer patients prospectively included in the MoMaTEC multicenter study. Day of surgery was dichotomized as early-week (Monday-Tuesday) or late-week (Wednesday-Friday), and evaluated as a discrete variable. Adjusted for patient age, Body Mass Index (BMI), FIGO stage, and histology, surgery performed later in the week was associated with 50.9% increased risk of all-cause death (p = 0.029). Among high-stage patients (FIGO stage III and IV), 5-year disease-specific survival proportions were 53.0% for early-week operated vs. 40.2% for late-week operated (p = 0.005 for difference). In multivariate survival analysis of high-stage patients, late-week surgery correlated with an increased risk of disease-specific death by 88.7% and all-cause death by 76.4% (p<0.017). Evaluating only patients who underwent lymphadenectomy, the adverse prognostic effect of being operated late-week remained for both disease-specific and all-cause death (HR 2.151 and HR 1.912, p = 0.004). Whether surgery was performed early- or late-week was not influenced by patient age, BMI, preoperative histology risk classification, FIGO stage or postoperative histology (all p>0.05). In conclusion, endometrial cancer surgery conducted late-week is associated with worse long-term outcome. Our findings are most evident among patients with higher FIGO stages, and patients who underwent more extensive surgical procedure (lymphadenectomy). With support from other studies, our results suggest that high-risk patients may benefit from surgery earlier in the week.Entities:
Mesh:
Year: 2017 PMID: 28771617 PMCID: PMC5542466 DOI: 10.1371/journal.pone.0182223
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinicopathological characteristics and demographics of endometrial cancer patients treated in the MoMaTEC* study.
| Characteristics | Total Cohort | Weekday of Surgery | p-value | ||||
|---|---|---|---|---|---|---|---|
| Monday-Tuesday | Wednesday-Friday | ||||||
| Number, % | Number, % | Number, % | |||||
| Total | 1302 | 100% | 723 | 100% | 579 | 100% | |
| <66 years | 643 | 49.4% | 365 | 50.5% | 278 | 48.0% | |
| ≥ 66 years | 659 | 50.6% | 358 | 49.5% | 301 | 52.0% | 0.376 |
| <25 kg/m2 | 229 | 35.1% | 123 | 36.9% | 106 | 33.2% | |
| ≥25 kg/m2 | 423 | 64.9% | 210 | 63.1% | 213 | 66.8% | 0.321 |
| Low-risk | 984 | 77.7% | 548 | 77.4% | 436 | 78.1% | |
| High-risk | 282 | 22.3% | 160 | 22.6% | 122 | 21.9% | 0.775 |
| Performed | |||||||
| Yes | 977 | 75.0% | 521 | 72.1% | 456 | 78.8% | |
| No | 325 | 25.0% | 202 | 27.9% | 123 | 21.2% | 0.006 |
| No treatment | 913 | 70.1% | 512 | 70.8% | 401 | 69.3% | |
| Adjuvant treatment | 389 | 29.9% | 211 | 29.2% | 178 | 30.7% | 0.541 |
| Stage I / II | 1114 | 85.6% | 626 | 86.6% | 488 | 84.3% | |
| Stage III / IV | 188 | 14.4% | 97 | 13.4% | 91 | 15.7% | 0.241 |
| Endometrioid grade 1–2 | 898 | 69.5% | 503 | 70.2% | 395 | 68.6% | |
| Endometrioid grade 3 | 156 | 12.1% | 80 | 11.2% | 76 | 13.2% | |
| Non-endometrioid | 239 | 18.5% | 134 | 18.7% | 105 | 18.2% | 0.535 |
| <50% | 802 | 66.4% | 454 | 68.3% | 348 | 64.2% | |
| ≥50% | 405 | 33.6% | 211 | 31.7% | 194 | 35.8% | 0.137 |
| No | 858 | 87.7% | 454 | 87.1% | 404 | 88.4% | |
| Yes | 120 | 12.3% | 67 | 12.9% | 53 | 11.6% | 0.548 |
Clinicopathological characteristics and demographics related to weekday of surgery for 1302 endometrial cancer patients undergoing primary surgical treatment. Weekday of surgery grouped as early-week (Monday and Tuesday) or late-week (Wednesday through Friday).
*MoMaTEC: Molecular Markers in Treatment of Endometrial cancer
aPearson χ2 test for two-sided significance.
bp = 0.131 when testing age as a continuous variable by Student’s t-test for equality of means.
cp = 0.779 when testing BMI as a continuous variable by Mann-Whitney U test for equality of medians.
dAdjuvant treatment comprising external radiation, internal radiation, chemotherapy, chemoradiation or hormonal treatment.
eFIGO = International Federation of Gynecology and Obstetrics (according to 2009 revision)
fLymph node metastasis evaluated among 977 patients with performed lymphadenectomy
Fig 1Disease-specific survival proportions in relation to weekday of surgery.
Weekday of surgery categorized as early-week (Monday and Tuesday) or late-week (Wednesday to Friday). A) All patients (n = 1302), B) patients with low FIGO stages (n = 1114), and C) patients with high FIGO stages (n = 188). For each category, the number of cases followed by the number of deaths is given in parenthesis. P-values are by the Kaplan-Meier estimation by the log-rank test.
Multivariate survival analyses of high stage endometrial cancer patients with weekday of surgery as a grouped variable.
| Disease-specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| Variable | n | Adjusted HR | 95% CI | P | Adjusted HR | 95% CI | P |
| 187 | 1.037 | 1.014–1.061 | 0.002 | 1.047 | 1.024–1.070 | <0.001 | |
| Endometrioid grade 1–2 | 76 | 1 | - | - | 1 | - | - |
| Endometrioid grade 3 | 38 | 1.915 | 0.984–3.728 | 0.056 | 1.569 | 0.834–2.952 | 0.162 |
| Non-endometrioid | 73 | 1.918 | 1.082–3.400 | 0.026 | 1.725 | 1.018–2.923 | 0.043 |
| Monday-Tuesday | 97 | 1 | - | - | 1 | - | - |
| Wednesday-Friday | 90 | 1.887 | 1.146–3.108 | 0.013 | 1.764 | 1.105–2.816 | 0.017 |
Multivariate disease-specific and overall survival analyses according to the Cox proportional hazards regression model for 187 endometrial cancer patients with high FIGO stages (stage III-IV). Weekday of surgery was dichotomized as either early-week (Monday and Tuesday), or late-week (Wednesday through Friday).
CI = Confidence Interval, FIGO = International Federation of Gynecology and Obstetrics, HR = Hazard Ratio.
aAge of primary treatment evaluated as a continuous variable.
bHistology evaluated in postoperatively acquired hysterectomy specimens
Multivariate survival analyses of high stage endometrial cancer patients with weekday of surgery as a discrete variable.
| Disease-specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| Variable | n | Adjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value |
| 187 | 1.039 | 1.016–1.063 | 0.001 | 1.049 | 1.026–1.072 | <0.001 | |
| Endometrioid grade 1–2 | 76 | 1 | - | - | 1 | - | - |
| Endometrioid grade 3 | 38 | 1.884 | 0.969–3.662 | 0.062 | 1.550 | 0.826–2.910 | 0.173 |
| Non-endometrioid | 73 | 1.898 | 1.072–3.362 | 0.028 | 1.709 | 1.009–2.895 | 0.046 |
| 187 | 1.242 | 1.012–1.524 | 0.038 | 1.197 | 0.986–1.453 | 0.069 | |
Multivariate disease-specific and overall survival analyses according to the Cox proportional hazards regression model for 187 endometrial cancer patients with high FIGO stages (FIGO stage III-IV). Weekday of surgery is evaluated as a discrete variable.
CI = Confidence Interval, FIGO = International Federation of Gynecology and Obstetrics, HR = Hazard Ratio.
aAge of primary treatment evaluated as a continuous variable.
bHistology evaluated in postoperatively acquired hysterectomy specimens
cWeekday of surgery evaluated as a discrete variable encoded 1 = Monday, 2 = Tuesday, 3 = Wednesday, 4 = Thursday, 5 = Friday
Multivariate survival analyses of all patients with performed lymphadenectomy.
| Disease-specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|
| Variable | n | Adjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value |
| 529 | 1.044 | 1.016–1.072 | 0.002 | 1.053 | 1.029–1.077 | <0.001 | |
| 529 | 0.982 | 0.936–1.030 | 0.453 | 1.000 | 0.961–1.040 | 0.982 | |
| Stage I/II | 443 | 1 | - | - | 1 | - | - |
| Stage III/IV | 86 | 6.545 | 3.809–11.245 | <0.001 | 4.497 | 2.824–7.160 | <0.001 |
| Endometrioid grade 1–2 | 340 | 1 | - | - | 1 | - | - |
| Endometrioid grade 3 | 75 | 4.429 | 1.925–10.188 | <0.001 | 1.972 | 1.012–3.843 | 0.046 |
| Non-endometrioid | 114 | 6.991 | 3.419–14.298 | <0.001 | 3.545 | 2.065–5.779 | <0.001 |
| Monday-Tuesday | 264 | 1 | - | - | 1 | - | - |
| Wednesday-Friday | 265 | 2.151 | 1.280–3.614 | 0.004 | 1.912 | 1.232–2.968 | 0.004 |
Multivariate disease-specific and overall survival analyses according to the Cox proportional hazards regression model for 529 endometrial cancer patients with performed lymphadenectomy. Weekday of surgery was dichotomized as either early-week (Monday and Tuesday), or late-week (Wednesday through Friday).
CI = Confidence Interval, FIGO = International Federation of Gynecology and Obstetrics, HR = Hazard Ratio.
aAge of primary treatment and BMI evaluated as continuous variables.
bHistology evaluated in postoperatively acquired hysterectomy specimens